ALZN Stock Forecast: Alzamend Neuro, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Alzamend Neuro, Inc. is $26. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Alzamend Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (56): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (13): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ALZN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ALZN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | Ascendiant Capital | Maintains | Buy | $25 → $26 |
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | $42 → $28 |
| 25 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Aug 2025 | Ascendiant Capital | Maintains | Buy | — |
| 17 Mar 2025 | Ascendiant Capital | Maintains | Buy | — |
| 16 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 11 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 12 Apr 2023 | Maxim Group | Initiates | Buy | $1.50 |
| 1 Oct 2021 | Ascendiant Capital | Initiates | Buy | $8.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ALZN.
This page is one stock. Monday covers all of them.
ALZN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ALZN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Alzamend Neuro, Inc. returned −61.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ALZN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −163.2%
- Return on assets
- −76.4%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alzamend Neuro, Inc. has a market value of $3.7M.
Revenue in the twelve months to 31 July 2026: $0.0.
Net income over the same four quarters: −$9.1M.
Free cash flow in the twelve months to 31 July 2026: −$6.8M.
Alzamend Neuro, Inc. employs 4 people.
Data provided by Twelve Data
ALZN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ALZN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Alzamend Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ALZN
What is the ALZN stock price forecast for 2026-2027?
The median 12-month analyst price target for Alzamend Neuro, Inc. is $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ALZN stock a buy right now?
Of the 1 analyst covering Alzamend Neuro, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alzamend Neuro, Inc. 27 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ALZN?
As at 21 Nov 2026, Alzamend Neuro, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (56 of 100).
Will ALZN stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $26, and Ticker Nerd's factor model ranks Alzamend Neuro, Inc. 27 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ALZN stock forecast for 2030?
No analyst covering Alzamend Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALZN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $26 over the next 12 months.
How has ALZN stock performed over the past year?
Alzamend Neuro, Inc. returned -61.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Alzamend Neuro, Inc. do?
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Alzamend Neuro’s current pipeline centers on AL001, a patented ionic cocrystal formulation that combines lithium, proline, and salicylate, and ALZN002, a cell-based therapeutic vaccine candidate designed to help restore the immune system’s ability to combat Alzheimer’s disease.
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Alzamend Neuro’s current pipeline centers on AL001, a patented ionic cocrystal formulation that combines lithium, proline, and salicylate, and ALZN002, a cell-based therapeutic vaccine candidate designed to help restore the immune system’s ability to combat Alzheimer’s disease. The company is working across major therapeutic areas including Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Its research and development activities are directed toward advancing novel product candidates intended to address conditions with significant unmet medical need in neuroscience and mental health. Headquartered in Atlanta, Georgia, Alzamend Neuro plays a specialized role in the biotech market as a developer of investigational therapies focused on the central nervous system and immune-based approaches to Alzheimer’s disease.
CEO Mr. Stephan Jackman · 4 employees · United States · https://www.alzamend.com